1427203-95-9

Basic information

• Product Name: C₁₉H₁₈ClNO₅S
• CAS NO: 1427203-95-9
• Molecular Weight: 407.875
• Mol File: 1427203-95-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₁₉H₁₈ClNO₅S(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₉H₁₈ClNO₅S(1427203-95-9)
• EPA Substance Registry System: C₁₉H₁₈ClNO₅S(1427203-95-9)

Safety Data

• Hazardous Substances Data: 1427203-95-9(Hazardous Substances Data)

Upstream product

• 25392-41-0 4-chloromethyl-7-hydroxycoumarin 
• 1427203-61-9 4-(chloromethyl)-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate 
• 75-31-0 isopropylamine 
• 2888-06-4 3-chlorophenylsulfonyl chloride 

Relevant articles and documents

Discovery, biological evaluation, and structure-activity and -selectivity relationships of 6′-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N- methylacetamides, a novel class of potent and selective monoamine oxidase inhibitors

The use of selective inhibitors of monoamine oxidase A (MAO-A) and B (MAO-B) holds a therapeutic relevance in the treatment of depressive disorders and Parkinson's disease (PD), respectively. Here, the discovery of a new class of compounds acting as monoamine oxidase inhibitors (MAO-Is) and bearing a 6′-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-alkylacetamide skeleton is reported. 6′-Sulfonyloxy derivatives exhibited outstanding affinities to MAO-A (7.0 nM 50 49 nM, much higher than moclobemide) and a pronounced MAO-A/B selectivity. The corresponding 6′-benzyloxy derivatives showed potent MAO-B inhibition and inverted selectivity profile. The rigid E-geometry of the exocyclic double bond allowed a more efficient binding conformation compared to more flexible and less active 2-(1-benzofuran-3-yl)-N- methylacetamide isomers and 4-N-methylcarboxamidomethylcoumarin analogues. Focused structural modifications and docking simulations enabled the identification of key molecular determinants for high affinity toward both MAO isoforms. These novel MAO-Is may represent promising hits for the development of safer therapeutic agents with a potential against depression, PD, and other age-related neurodegenerative pathologies.